Insider buying last 90 days
No open-market insider purchases were filed for FBRX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every FBRX insider filing, plotted on the chart in Gekko.Open FBRX in Gekko
No recent trading data for FBRX. The last close Gekko holds is Aug 26, 2026, so the figures on this page may be out of date.
NASDAQ: FBRX
Forte Biosciences (FBRX) Stock Analysis & Forecast
Aug 26 close
$76.99+0.02 (0.0%)
Gekko Brief
Aug 26 closeForte Biosciences closed at $76.99 on 26 August 2026, 0% on the day. The price sits above both the 50-day ($52.74) and 200-day ($32.21) moving averages, inside a 52-week range of $10.11 to $77.20. The GekkoIndex reads 43.4, in the Distribution zone, up 3 points over five sessions. Gekko Fair Value is $41.63, so the price is 84.9% above it.
The next earnings report is due on 13 November 2026, 32 days away. Over the last 8 reports the company beat the earnings estimate 3 times, with an average move of 5% across the report. Seasonally, the next 20 trading days from this point averaged -7.5% over the last 5 years, rising in 1 of them.
5 firms rate the stock: 1 buy, 4 hold and 0 sell, with a consensus target of $73.00. A typical daily move is about 0.1%, and a typical 20-day move about 13.8%. On the swing-trade checklist, 2 items read supportive and 3 read as a headwind (gekkoindex, fair value, seasonality).
A plain summary of the figures as of the Aug 26, 2026 close.
Forte Biosciences price vs fair value
Close $76.99200-day averageGekko Fair Value $41.63
Forte Biosciences quick facts
- Market cap
- $1.63B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$4.57
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 2.65
- Volume
- 1.40M avg 1.57M
- 1-year return
- +580.1%
- Typical daily move
- ±0.1%
- Typical 20-day move
- ±13.8%
- 50-day average
- $52.74
- 200-day average
- $32.21
- Next earnings
- Nov 13
- Shares outstanding
- 21.23M
Forte Biosciences swing-trade checklist
Forte Biosciences scores 2 supportive, 0 mixed and 3 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive0 mixed3 headwinds
- Trendsupportive
Above 50 and 200-day
Close $76.99 is above the 50-day ($52.74) and 200-day ($32.21) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexheadwind
43.4, Distribution
Reading 43.4 is in the Distribution zone.
See the GekkoIndex - Fair valueheadwind
84.9% above
Price is 84.9% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 32 days
Next report Nov 13, 2026, 32 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−7.5% on average
From this point in the calendar, the next 20 trading days averaged −7.5% over 5 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Forte Biosciences stock chart and price history
Forte Biosciences closed at $76.99 on Aug 26, 2026, +580.1% over the past year, inside a 52-week range of $10.11 to $77.20.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +0.4%
- 3 months
- +258.6%
- 6 months
- +170.7%
- 1 year
- +580.1%
The full FBRX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open FBRX in Gekko
Follow Forte Biosciences through every session
Put FBRX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track FBRX in GekkoFree for 7 days. No credit card required.
About Forte Biosciences
Forte Biosciences is a clinical-stage biopharmaceutical company working on treatments for autoimmune conditions. Its central effort is the FB-102 program, which is being developed to address disorders such as vitiligo and alopecia areata. The company is known for this program as its primary focus.
As a clinical-stage firm, Forte Biosciences centers its activity on advancing FB-102 through development rather than selling commercial products at this stage. Its work is directed at addressing autoimmune diseases, with vitiligo and alopecia areata named as particular targets of the program.
Forte Biosciences is headquartered in Dallas, Texas. Its shares are listed on the NASDAQ under the ticker FBRX.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- fortebiorx.com
Forte Biosciences GekkoIndex: the smart money zone
Forte Biosciences’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 43.4, in the Distribution zone, up 3 points over five sessions.
43.4Distribution
Up 3 points over five sessions.
Reading for Aug 26, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 56 | Not available | |||
| Accumulation | 225 | Not available | |||
| Neutral | 311 | +4.6% | +15.0% | ||
| Distribution (current zone) | 51 | +7.3% | +22.4% | ||
| Selling | 8 | Too few readings yet | |||
Average FBRX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Distribution readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Distribution zone: Institutions potentially offloading. About the five zones →
See every daily GekkoIndex reading plotted over the FBRX price, zone by zone.Track FBRX in Gekko
Is Forte Biosciences stock overvalued? Gekko Fair Value
Forte Biosciences trades 84.9% above Gekko Fair Value of $41.63, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Forte Biosciences shares are worth, recalculated every trading day.
$41.63
Gekko Fair Value, Sep 5, 2026
84.9% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open FBRX in Gekko
Forte Biosciences insider and Congress trading
No open-market insider purchases were filed for Forte Biosciences, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in FBRX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for FBRX, plotted on the chart in Gekko.Open FBRX in Gekko
Buybacks
Forte Biosciences has been buying back its own shares.
- Bought back, quarter ended Dec 31, 2024
- $2K
- As a share of market cap
- 0.00%
From company filings.
Forte Biosciences earnings: next date and track record
Forte Biosciences reports on Nov 13, 2026 (32 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 13, 2026
32 days away
- EPS estimate
- −$0.90
3 of 8reports beat the EPS estimate
±5%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| May 11, 2026 | −$1.24 est −$1.16 | — | +1.1% |
| Mar 31, 2026 | −$1.45 est −$1.15 | — | −5.5% |
| Dec 31, 2025 | −$1.45 est −$1.15 | — | −10.1% |
| Nov 14, 2025 | −$0.99 est −$1.04 | — | +4.7% |
| Aug 14, 2025 | −$0.96 est −$1.21 | — | +9.5% |
| May 15, 2025 | −$1.37 est −$0.89 | — | +3.3% |
| Mar 28, 2025 | −$1.17 est −$0.14 | — | −1.9% |
| Mar 24, 2025 | −$2.45 est −$4.55 | — | +4.2% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Forte Biosciences stock forecast and analyst price targets
Analysts’ average 12-month price target for Forte Biosciences is $73.00, −5.2% from the last close, from 5 firms rating the stock in the last 90 days.
$73.00consensus 12-month target, −5.2% from the last close
Now $76.99Avg $73.00
Low $75High $77
Each firm’s latest rating in the last 90 days: 5 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Aug 12 | Barclays | $77 | 0.0% |
| Aug 12 | Barclays | $77 | 0.0% |
| Jul 28 | Barclays | $77 | 0.0% |
| Jul 27 | TD Cowen | $77 | 0.0% |
| Jul 27 | Evercore ISI | $77 | 0.0% |
+22.4%average 20-day move after past Distribution readings
−7.5%average move over the next 20 trading days in the last 5 years
±0.1%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Forte Biosciences seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Forte Biosciences averaged −7.5% across the last 5 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −9.0% | 0 of 5 |
| Next 10 trading days | −9.5% | 0 of 5 |
| Next 15 trading days | −6.7% | 1 of 5 |
| Next 20 trading days | −7.5% | 1 of 5 |
| Next 30 trading days | +29.7% | 2 of 5 |
For scale, FBRX’s typical 20-trading-day move in either direction is about 13.8%.
Forte Biosciences market cap and key statistics
Forte Biosciences’s market cap is $1.63B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $1.63B
- EPS, TTM
- −$4.57
- Gekko Fair Value
- $41.63
Trading
- Volume
- 1.40M
- Avg volume, 20 days
- 1.57M
- 52-week high
- $77.20
- 52-week low
- $10.11
- Shares outstanding
- 21.23M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -62.3%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 2.65
- Typical daily move
- ±0.1%
- Typical 20-day move
- ±13.8%
Forte Biosciences stock news this week
Coverage of Forte Biosciences this week reads positive: 5 positive, 1 neutral and 0 negative headlines.
- Squarepoint Ops LLC Reduces Position in Forte Biosciences, Inc. $FBRXDefense World, Sep 24
- Argenx (ENXTBR:ARGX) Completes Forte Biosciences AcquisitionYahoo Finance, Aug 27
- argenx Completes Acquisition of Forte Biosciences, Inc.Barchart.com, Aug 27
- Forte Biosciences earnings on deck as argenx deal loomsInvesting.com, Aug 23
- What Forte Biosciences (FBRX) bankers see in $77 cash bidStock Titan, Aug 21
- Forte Biosciences (FBRX) cash tender clears antitrustStock Titan, Aug 19
Forte Biosciences peers
Forte Biosciences’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Forte Biosciences stock FAQ
What is Forte Biosciences’s market cap?
Forte Biosciences’s market cap is $1.63B at the Aug 26, 2026 close of $76.99, with 21.23M shares outstanding.
What is the Forte Biosciences stock forecast?
The consensus analyst 12-month price target for Forte Biosciences is $73.00, −5.2% from the last close. Of the 5 firms that rated the stock in the last 90 days, 1 rate it a buy, 4 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Forte Biosciences stock overvalued or undervalued?
On Gekko’s estimate Forte Biosciences is overvalued: the Aug 26, 2026 close of $76.99 is 84.9% above Gekko Fair Value of $41.63. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Forte Biosciences report earnings next?
Forte Biosciences is expected to report on Nov 13, 2026 (32 days away). Analysts expect earnings of −$0.90 per share. Forte Biosciences beat the earnings estimate in 3 of its last 8 reports, moving 5% on average across the report.
What is Forte Biosciences’s 52-week high and low?
Forte Biosciences’s 52-week high is $77.20 and its 52-week low is $10.11; it closed at $76.99 on Aug 26, 2026, +580.1% over the past year. Over the last five years the shares peaked at $786.75 on Sep 2, 2021.
Is Forte Biosciences stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk) and 3 as headwinds (gekkoindex, fair value and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Forte Biosciences the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.